OneMedNet CEO Letter Says The Company Plans To Leverage Palantir's AI Platform To Accelerate The Development Of Its Regulatory-Grade, AI-Ready Real-World Data Network

OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), the leading curator and provider of one of the world's largest regulatory-grade, AI-ready Real-World Data (RWD) network announced today that Aaron Green, President and CEO, issued the following letter to shareholders and other stakeholders of the Company:

Dear OneMedNet Shareholders, Partners, and Family,

2025 has been a year of focus for OneMedNet – focus on our platform, focus on our people, and focus on executing our strategic plan to lay the foundation for growth in 2026. As part of this strategic execution, in October 2025, we announced our selection of Palantir's AI platform (AIP), which has allowed us to accelerate our platform development with a planned launch of our AI-driven multimodal subscription search in the new year. We believe this first-of-its-kind platform will revolutionize the way life sciences organizations interact with data from provider facilities.

2025 Highlights:

• Improved Financial Foundation: Reduced our total liabilities by approximately $19.6 million, representing an approximate 75% reduction by the end of 2025, compared to total liabilities on December 31, 2024.
• Platform: Accelerated platform development with the selection and integration of Palantir (PLTR).
• Network Expansion: Continued expansion of our healthcare provider network, with a 37% year-over-year (YOY) increase and a total of 186 million clinical exams within the network from over 2,130 healthcare partner sites.
• People: Hired a proven sales leader and expanded the commercial team to support scaling the business. Reorganized and grew our operations team to be technology lead improving delivery speed and efficiency.

What Sets Us Apart

• Proven Customer Success: Driving repeat orders and increasing Master Service Agreements (MSAs) from leading life sciences and healthcare innovator organizations, positioning us as the vendor of choice as evidenced by shortened sales cycles, increased deal sizes, and great relationships with repeat customers.
• AI-Powered Data Access: Leveraging Palantir's platform for smart conversational queries of live, de-identified real-world data directly from hospitals and clinics in near real-time, delivering curated regulatory-grade datasets that accelerate drug development, power AI model training, and support regulatory submissions.
• Longitudinal Patient Records: Access live data that follows patients over time, enabling real-time tracking of patient journeys and ongoing updates to reflect the latest clinical developments—unlike competitors' stale data trapped in stagnant data lakes.
• Multimodal iRWD™: Our indexed Real-World Data (iRWD) that integrates multiple data modalities—such as medical imaging (e.g., MRI, CT scans), lab results, clinical notes, electronic health records, and other structured and unstructured sources—providing a comprehensive view of patient health. This is enhanced by custom cohort matching and AI-powered refinement to ensure precise, high-quality datasets tailored to specific research needs.

The Opportunity Ahead

• Market Demand Trends: We are seeing a clear trend in inbound demand for large-scale RWD to train, validate, and monitor AI models, alongside growing interest in long-term, subscription-based data relationships. This shift toward recurring access models supports durable customer relationships, enhances visibility, and directly contributes to the growth of annual recurring revenue (ARR). This is visible from our third quarter bookings, which increased eight fold YOY from 2024 to 2025.
• Platform Expansion Strategy: In 2026, we plan to extend our platform by introducing additional services adjacent to data cohort building and delivery, including tools for data sources (hospitals and clinics) to analyze their own data, while expanding into Health Economics and Outcomes Research (HEOR) focused solutions, including market surveillance and post-market evidence products.
• Growing Need for RWD: The need for Real-World Data (RWD) has never been greater. The traditional model of lengthy, expensive clinical trials is being disrupted, as regulators such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) increasingly encourage the use of Real-World Evidence (RWE) as part of the regulatory approval and post-market surveillance process.
• Advancing Our Mission: Our continued investment in the platform advances OneMedNet's mission to remove the friction that exists today between care providers and researchers—significantly reducing time to market for new drugs, medical devices, and healthcare artificial intelligence solutions.
• Unlocking Market Potential: At the same time, access to healthcare data remains a critical bottleneck in unlocking the estimated $868 billion AI-driven healthcare market by 2030¹. OneMedNet is positioned at the forefront of this opportunity by leveraging Palantir platform to combine our expansive provider network with advanced analytics, delivering secure, regulatory-grade, large-scale RWD through a modern subscription platform.